Licensing Opportunity: Replication-Competent Adenovirus Type 4 SARS-CoV-2 Vaccines and Their Use

National Institute of Allergy and Infectious Diseases sent this bulletin at 04/14/2021 10:58 AM EDT

Leading Research to Understand, Treat, and Prevent Infectious, Immunologic, and Allergic Diseases

Visit us on the Web

Replication-Competent Adenovirus Type 4 SARS-CoV-2 Vaccines and Their Use

Licensing Opportunity

No alternative text description for this image

Colorized scanning electron micrograph of a cell heavily infected with SARS-CoV-2 virus particles (red), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID

NIAID researchers have produced recombinant adenovirus type 4 (Ad4) vectors that deliver SARS-CoV-2 spike proteins for human administration. These recombinant vaccines permit rapid development of high levels of neutralizing antibodies to SARS-CoV-2 in experimental animals. This vaccine is designed to improve the durability of the immune response by inducing mucosal and systemic immunity. Further, this system should be incredibly simple and efficient when producing vaccine at scale.

Read more about this exciting opportunity at https://lnkd.in/gpcJJGJ or contact Christopher Kornak, J.D., chris.kornak@nih.gov or 240-627-3705.

Follow NIAID Tech Transfer on LinkedIn.

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com.

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).